Sage Therapeutics (Nasdaq: SAGE) scored a massive win for its investors and potentially for patients too as its Phase III trials in postpartum depression met their primary endpoints.
The US clinical-stage biotech closed 54% up on Thursday at $96.65 after reporting the Hummingbird Program trial results with its proprietary IV formulation of brexanolone (formerly SAGE-547).
By achieving a mean reduction from baseline in the Hamilton Rating Scale for Depression (HAM-D) total score compared to placebo at 60 hours, brexanolone met both primary endpoints.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze